Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Public ClinicalTrials.gov record NCT01234337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Study identification
- NCT ID
- NCT01234337
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 537 participants
Conditions and interventions
Conditions
Interventions
- Capecitabine Drug
- Placebo Drug
- Sorafenib (Nexavar, BAY43-9006) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2011
- Primary completion
- May 11, 2014
- Completion
- Oct 19, 2017
- Last update posted
- Nov 5, 2018
2011 – 2017
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Greenbrae | California | 94904-2007 | — |
| Not listed | Sylmar | California | 91342 | — |
| Not listed | West Palm Beach | Florida | 33407 | — |
| Not listed | Joliet | Illinois | 60435 | — |
| Not listed | Evansville | Indiana | 47713 | — |
| Not listed | Louisville | Kentucky | 40207 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Boston | Massachusetts | 02115-6084 | — |
| Not listed | Jackson | Mississippi | 39202 | — |
| Not listed | Springfield | Missouri | 65804 | — |
| Not listed | Albuquerque | New Mexico | 87131 | — |
| Not listed | Lake Success | New York | 11042 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Bristol | Tennessee | 37620 | — |
| Not listed | Memphis | Tennessee | 38120 | — |
| Not listed | El Paso | Texas | 79905 | — |
| Not listed | Burlington | Vermont | 05405 | — |
| Not listed | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 134 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01234337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2018 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01234337 live on ClinicalTrials.gov.